Stifel Reiterates Hold Rating on MacroGenics (MGNX): "MGC026 dose-escalation/expansion data should read well"

March 10, 2026 5:03 PM

Stifel analyst Stephen Willey reiterated a Hold rating and $4.00 price target on MacroGenics (NASDAQ: MGNX)The analyst commented, "The provision ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found